Glasgow, UK-based MGB Biopharma Ltd has completed a new funding round, enabling it to advance an ongoing Phase 2a trial of its candidate antibiotic MGB-BP-3 and prepare for the next stage of development. The candidate drug is being developed to treat Clostridium difficile-associated disease.
